KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $368.7 million.

  • Biomarin Pharmaceutical's Cash from Operations rose 6646.35% to $368.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $914.0 million, marking a year-over-year increase of 12039.63%. This contributed to the annual value of $572.8 million for FY2024, which is 25969.14% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Cash from Operations stood at $368.7 million for Q3 2025, which was up 6646.35% from $185.3 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Cash from Operations ranged from a high of $368.7 million in Q3 2025 and a low of -$73.9 million during Q1 2023
  • For the 5-year period, Biomarin Pharmaceutical's Cash from Operations averaged around $102.2 million, with its median value being $97.1 million (2021).
  • In the last 5 years, Biomarin Pharmaceutical's Cash from Operations skyrocketed by 84708.44% in 2021 and then crashed by 14002.31% in 2022.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Cash from Operations stood at $11.2 million in 2021, then crashed by 39.3% to $6.8 million in 2022, then surged by 305.0% to $27.5 million in 2023, then surged by 575.42% to $185.6 million in 2024, then soared by 98.62% to $368.7 million in 2025.
  • Its last three reported values are $368.7 million in Q3 2025, $185.3 million for Q2 2025, and $174.4 million during Q1 2025.